NO20050418L - Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet - Google Patents

Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet

Info

Publication number
NO20050418L
NO20050418L NO20050418A NO20050418A NO20050418L NO 20050418 L NO20050418 L NO 20050418L NO 20050418 A NO20050418 A NO 20050418A NO 20050418 A NO20050418 A NO 20050418A NO 20050418 L NO20050418 L NO 20050418L
Authority
NO
Norway
Prior art keywords
tie2
tek
pyrimidines
activity
formula
Prior art date
Application number
NO20050418A
Other languages
English (en)
Inventor
Richard William Arthur Luke
Barry Raymond Hayter
Clifford David Jones
William Mccoull
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218168A external-priority patent/GB0218168D0/en
Priority claimed from GB0312356A external-priority patent/GB0312356D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20050418L publication Critical patent/NO20050418L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Det er beskrevet en forbindelse med formel (1), hvor A sammen med karbonatomene hvortil de er bundet danner en kondensert 5-leddet heteroarylring, hvor nevnte heteroarylring inneholder en eller to heteroatomer valgt fra 0, N og S, og hvor den 5-leddete ringen inneholdende G er bundet til ringen dannet av A i meta posisjonen til brohode karbonatomet merket # i formel (i): G er valgt fra 0, S og NR5; Z er valgt fra N og CR6; Q1 er valgt fra eventuelt substituert aryl og heteroaryl og substituentene R1 til R6 er som definert i beskrivelsen for anvendelse ved dannelse av en anti-angiogen effekt i et varmblodig dyr så som mennesket.
NO20050418A 2002-08-06 2005-01-25 Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet NO20050418L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0218168A GB0218168D0 (en) 2002-08-06 2002-08-06 Compounds
GB0312356A GB0312356D0 (en) 2003-05-30 2003-05-30 Compounds
PCT/GB2003/003275 WO2004013141A1 (en) 2002-08-06 2003-08-01 Condensed pyridines and pyrimidines with tie2 (tek) activity

Publications (1)

Publication Number Publication Date
NO20050418L true NO20050418L (no) 2005-04-28

Family

ID=31497259

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050418A NO20050418L (no) 2002-08-06 2005-01-25 Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet

Country Status (15)

Country Link
US (1) US7427616B2 (no)
EP (1) EP1537112B1 (no)
JP (1) JP2005538118A (no)
KR (1) KR20050067383A (no)
AR (1) AR041189A1 (no)
AT (1) ATE323702T1 (no)
AU (1) AU2003246972A1 (no)
BR (1) BR0313078A (no)
CA (1) CA2494421A1 (no)
DE (1) DE60304718T2 (no)
IL (1) IL166521A0 (no)
MX (1) MXPA05001389A (no)
NO (1) NO20050418L (no)
TW (1) TW200407116A (no)
WO (1) WO2004013141A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230089D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
GB0402518D0 (en) 2004-02-05 2004-03-10 Astrazeneca Ab Therapeutic agents
WO2005080346A1 (en) * 2004-02-12 2005-09-01 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
US7517888B2 (en) 2004-04-28 2009-04-14 Cv Therapeutics, Inc. A1 adenosine receptor antagonists
CA2566160C (en) 2004-05-27 2011-01-18 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
WO2005121140A1 (en) 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
TW200615268A (en) * 2004-08-02 2006-05-16 Osi Pharm Inc Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
ES2401138T3 (es) 2004-08-13 2013-04-17 Genentech, Inc. Inhibidores basados en tiazol de enzimas que usan ATP
ES2465469T3 (es) 2005-01-14 2014-06-05 Gilead Connecticut, Inc. Diaril ureas 1,3-sustituidas como moduladores de la actividad quinasa
CN101389324A (zh) * 2005-12-23 2009-03-18 史密丝克莱恩比彻姆公司 Aurora激酶的氮杂吲哚抑制剂
AU2007240568A1 (en) * 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
WO2009098715A2 (en) 2008-01-11 2009-08-13 Natco Pharma Limited Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
EP2671891A3 (en) 2008-06-27 2014-03-05 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CA2731228A1 (en) 2008-07-22 2010-01-28 Biocryst Pharmaceuticals, Inc. Synthetic intermediates and processes
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
AU2011216404B2 (en) 2010-02-17 2016-04-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2603216A4 (en) * 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
PL2614052T3 (pl) 2010-09-08 2015-06-30 Bristol Myers Squibb Co Nowe analogi piperazyny jako środki przeciw wirusowi grypy o szerokim spektrum
CA2812935A1 (en) 2010-09-28 2012-04-05 Bristol-Myers Squibb Company Novel piperazine analogs with substituted heteroaryl groups as broad-spectrum influenza antivirals
EP2733146A1 (en) * 2012-11-20 2014-05-21 KTB Tumorforschungsgesellschaft mbH Thioether derivatives as protein kinase inhibitors
WO2014079545A1 (en) * 2012-11-20 2014-05-30 Ktb Tumorforschungsgesellschaft Mbh Thioether derivatives as protein kinase inhibitors
AR097138A1 (es) 2013-07-15 2016-02-24 Basf Se Compuestos plaguicidas
CA2921199A1 (en) * 2013-08-27 2015-03-05 Bristol-Myers Squibb Company Ido inhibitors
WO2016100495A1 (en) * 2014-12-17 2016-06-23 Duquesne University Of The Holy Spirit CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTITUMOR AGENTS
EP3632908A1 (en) 2018-10-02 2020-04-08 Inventiva Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
KR20210095649A (ko) * 2018-11-20 2021-08-02 조지타운 유니버시티 신경 변성, 심근 변성 및 리소좀 축적 장애를 치료하기 위한 조성물 및 방법

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD287503A5 (de) 1988-06-13 1991-02-28 Karl-Marx-Universitaet Leipzig,De Verfahren zur herstellung von 4-amino-2-mercapto-thieno-/2,3-d/pyrimidinen bzw. 4-amino-2-alkylthio-thieno/2,3-d/-pyrimidinen
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
WO1998007835A2 (en) 1996-08-21 1998-02-26 Sugen, Inc. Crystal structures of a protein tyrosine kinase
IL131582A0 (en) 1997-03-19 2001-01-28 Basf Ag Pyrrolo [2,3d] pyrimidines and their use as tyrosine kinase inhibitors
HUP0100287A3 (en) * 1997-11-11 2003-04-28 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
AU3859999A (en) 1998-05-14 1999-11-29 G.D. Searle & Co. 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors
SK18542000A3 (sk) 1998-06-04 2001-12-03 Abbott Laboratories Protizápalové zlúčeniny inhibujúce bunkovú adhéziu
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
PL346700A1 (en) 1998-09-18 2002-02-25 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors
SK3852001A3 (en) 1998-09-18 2003-03-04 Basf Ag 4-Aminopyrrolopyrimidines as kinase inhibitors
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP2002541078A (ja) 1999-04-02 2002-12-03 ユーロ−セルティーク，エス．エー． ホスホジエステラーゼｉｖ阻害活性を有するプリン誘導体
WO2000059902A2 (en) 1999-04-02 2000-10-12 Du Pont Pharmaceuticals Company Aryl sulfonyls as factor xa inhibitors
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
TR200201413T2 (tr) 1999-09-17 2003-02-21 Millennium Pharmaceuticals, Inc. Faktör Xa' nın inhibitörleri.
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
NZ517758A (en) * 1999-09-17 2004-06-25 Abbott Gmbh & Co Pyrazolopyrimidines useful as therapeutic agents
PL354241A1 (en) 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
PL355912A1 (en) 1999-11-22 2004-05-31 Smithkline Beecham Plc. Novel compounds
AU2441701A (en) 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Purine derivatives
IL150062A0 (en) * 1999-12-17 2002-12-01 Ariad Pharma Inc Proton pump inhibitors
AU763356C (en) 1999-12-27 2004-08-26 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
EP1244668B1 (en) 2000-01-07 2006-04-05 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
WO2001072778A2 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Method of identifying inhibitors of tie-2
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
AU2001288735A1 (en) 2000-09-08 2002-03-22 Glaxo Group Limited Crystallized cytoplasmic tie2 receptor tyrosine kinase domain and method of determining and designing modulators of the same
WO2002039956A2 (en) 2000-11-15 2002-05-23 Rutgers, The State University Of New Jersey Black tea extract for prevention of disease
EP1341771A2 (en) 2000-11-29 2003-09-10 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
WO2002085909A1 (en) 2001-04-20 2002-10-31 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
WO2003000187A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
US7427623B2 (en) 2001-09-11 2008-09-23 Smithkline Beecham Corporation 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof
ES2307780T3 (es) 2001-09-21 2008-12-01 Smithkline Beecham Corporation Compuestos quimicos.
MXPA04003954A (es) 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
WO2003055860A1 (en) 2001-12-21 2003-07-10 Vernalis (Cambridge) Limited 3,4-diarylpyrazoles and their use in the therapy of cancer
TW200306191A (en) 2002-02-22 2003-11-16 Teijin Ltd Pyrrolopyrimidine derivatives
KR100714519B1 (ko) 2002-03-07 2007-05-07 에프. 호프만-라 로슈 아게 이환 피리딘 및 피리미딘 ｐ38 키나아제 억제제

Also Published As

Publication number Publication date
AU2003246972A1 (en) 2004-02-23
CA2494421A1 (en) 2004-02-12
AR041189A1 (es) 2005-05-04
WO2004013141A1 (en) 2004-02-12
IL166521A0 (en) 2006-01-15
KR20050067383A (ko) 2005-07-01
DE60304718T2 (de) 2007-04-26
EP1537112B1 (en) 2006-04-19
US20050256140A1 (en) 2005-11-17
BR0313078A (pt) 2005-07-12
DE60304718D1 (de) 2006-05-24
MXPA05001389A (es) 2005-04-28
ATE323702T1 (de) 2006-05-15
EP1537112A1 (en) 2005-06-08
JP2005538118A (ja) 2005-12-15
US7427616B2 (en) 2008-09-23
TW200407116A (en) 2004-05-16

Similar Documents

Publication Publication Date Title
NO20050418L (no) Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet
ATE388146T1 (de) 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
DE602005024239D1 (de) Pyrimidin-verbindungen als purin-rezeptorantagonisten
NO20061126L (no) Aminopyroner og deres anvendelse som ATM-inhibitorer
TW200800949A (en) Macrocylic inhibitors of hepatitis C virus
NO20084302L (no) 2-(syklisk amino)-pyrimidonderivater som TPK1-inhibitorer
NO20080456L (no) Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer
ES2368594T3 (es) Derivados sustituidos de ciclohexilmetilo.
CY1107008T1 (el) Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii
PE20080772A1 (es) Nuevos derivados de bipiridina sustituidos y su uso
AR035111A1 (es) Procedimiento para preparar un compuesto de pirimidinona
NO20066015L (no) Fuserte heterosykliske forbindelser
ATE503746T1 (de) Neue imidazolidinderivate
WO2008136444A1 (ja) 縮合複素環誘導体
WO2003028459A8 (de) Nicotinsäure-heterocyclyl-amide und analogue pyrimidin-derivate als schädlingsbekämpfungsmittel
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
TW200730527A (en) Fused heterocyclic compound
ATE461192T1 (de) Chinoloncarbonsäureverbindungen mit 5-ht4- rezeptoragonistischer wirkung
MA33501B1 (fr) Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
NO20062202L (no) Amidometylsubstituerte 2-(4-sulfonylamino)-3-hydroksy-3,4-dihydro-2H-kromen-6-yl-derivater, fremgangsmate og mellomprodukter for deres fremstilling, og legemidler som inneholder disse forbindelsene
DE60336735D1 (de) Neue biologischaktive molekü le
ATE482933T1 (de) Sulfopyrrolderivate
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
DE60326933D1 (de) Kondensierte bicyclische pyrimidinderivate
CY1113031T1 (el) Παραγωγα ν-αμινοϊμιδαζολιου που αναστελουν ηιv

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application